Ramino-Bio
Oral drug for treating cardio-metabolic disease and rare MSUD
Company Overview
Snapshot
Founded in September 2018, Ramino-Bio operates with 1–10 employees. The company has secured funding across one round from 6 investors, including Johnson & Johnson Innovation and RMGP Biopharma Investment Fund. Ramino-Bio is currently in preclinical stages with plans for first-in-human studies within 18 months for its lead candidate.
Business overview
Ramino-Bio is a Health Tech & Life Sciences company focused on developing oral drugs for cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). The company's technology targets unmet needs in metabolic diseases by addressing elevated Branched-chain amino acid (BCAA) levels. Ramino-Bio operates within the Pharmaceuticals sector, specifically in Drugs Discovery & Development, and serves the Healthcare & Life Sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is Ramino-Bio's primary focus?
- Ramino-Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD), focusing on the emerging field of novel elevated BCAA (Branched-chain amino acid) levels.
- When was Ramino-Bio founded?
- Ramino-Bio was founded in September 2018.
- What is the current stage of Ramino-Bio's product development?
- Ramino-Bio is currently in preclinical stages with a druggable lead compound showing in-vivo efficacy. First-in-human studies are planned within 18 months for their lead candidate.
- Which investors participated in Ramino-Bio's funding round?
- In September 2018, Ramino-Bio received funding from investors including Johnson & Johnson Innovation.
- What is Ramino-Bio's status as of November 2025?
- As of November 2025, Ramino-Bio ceased to operate.